Human Apo AV ELISA

Human Apo AV ELISA

96-well plate

Apolipoprotein AV (Apo AV) is a newer member of the plasma apolipoprotein family. Mature human Apo AV is a 39 kD protein with 343 residues and displays 27% sequence identity with human A-IV. This protein is expressed in the liver and secreted into circulation with relatively low circulating levels compared to other apolipoproteins. Recent studies have demonstrated that Apo AV plays very important roles in the regulation of plasma triglyceride levels in rodents and humans.

• Radioimmunoassay
• ELISA

20 µL sample size (serum /plasma 1:5 diluted)~3.5 hour assay, Room Temperature

Human

Unless otherwise stated in our catalog or other company documentation accompanying the product(s), our products are intended for research use only and are not to be used for any other purpose, which includes but is not limited to, unauthorized commercial uses, in vitro diagnostic uses, ex vivo or in vivo therapeutic uses or any type of consumption or application to humans or animals.

The protein encoded by this gene is an apolipoprotein and an important determinant of plasma triglyceride levels, a major risk factor for coronary artery disease. It is a component of high density lipoprotein and is highly similar to a rat protein that is upregulated in response to liver injury. This gene uses alternate polyadenylation sites and is located proximal to the apolipoprotein gene cluster on chromosome 11q23.

FUNCTION: SwissProt: Q6Q788 # Minor apolipoprotein mainly associated with HDL and to a lesser extent with VLDL. May also be associated with chylomicrons. Important determinant of plasma triglyceride (TG) levels by both being a potent stimulator of apo-CII lipoprotein lipase (LPL) TG hydrolysis and a inhibitor of the hepatic VLDL-TG production rate (without affecting the VLDL-apoB production rate) (By similarity). Activates poorly lecithin:cholesterol acyltransferase (LCAT) and does not enhance efflux of cholesterol from macrophages.
SIZE: 366 amino acids; 41213 Da
SUBCELLULAR LOCATION: Secreted.
TISSUE SPECIFICITY: Liver.
DISEASE: SwissProt: Q6Q788 # Defects in APOA5 are a cause of susceptibility to familial hypertriglyceridemia [MIM:145750]. It is a coronary heart disease risk factor. On a regular diet the patient demonstrates increased plasma VLDL. Plasma triglycerides are persistently increased, while plasma cholesterol and phospholipids are usually within normal limits. & Defects in APOA5 are a cause of hyperlipoproteinemia type 5 [MIM:144650]. Hyperlipoproteinemia type 5 is characterized by increased amounts of chylomicrons and very low density lipoprotein (VLDL) and decreased low density lipoprotein (LDL) and high density lipoprotein (HDL) in the plasma after a fast. Numerous conditions cause this phenotype, including insulin-dependent diabetes mellitus, contraceptive steroids, alcohol abuse, and glycogen storage disease type 1A (GSD1A) [MIM:232200].
SIMILARITY: SwissProt: Q6Q788 ## Belongs to the apolipoprotein A1/A4/E family.
MISCELLANEOUS: Induced in early phase of liver regeneration.

85-117%

1.0 ng/mL

Q6Q788

• Intra-assay 2.8 – 6.4%
• Inter-assay 5.3 – 12.4%

78-105%

• Colorimetric
• Radioactive

• APOA5
• ApoA-V
• RAP3
• APOA-V
• MGC126838
• MGC126836
• ApoAV
• APOAV

Human Apo AV ELISA

4.96 – 300 ng/mL

NM_052968.3

No species cross-reactivity is observed in the assay to rat, mouse, canine, porcine, or sheep Apo AV. However, there is a high degree of sample cross-reactivity observed to non-human primate samples which has not been explored or validated.

Apo AV